Predictors of Prosthetic Valve Endocarditis following Transcatheter Aortic Valve Replacement: A Meta-Analysis
DOI:
https://doi.org/10.1532/hsf.3461Keywords:
Prosthetic valve endocarditis, Transcatheter aortic valve replacement, Meta-analysis, Risk factorAbstract
Background: Transcatheter aortic valve replacement (TAVR) has gained increasing acceptance for patients with aortic disease. A rare but fatal complication prosthetic valve endocarditis (PVE) could greatly influence the clinical outcomes of TAVR. This meta-analysis aims to pin down the predictors of PVE in TAVR patients.
Methods: We performed a systematic search for studies that reported the incidence and risk factors of PVE after TAVR. Data on studies, patients, baseline characteristics, and procedural characteristics were abstracted. Crude risk ratios (RRs) and 95% confidence intervals for each predictor were calculated by the use of random-effects models.
Heterogeneity assumption was assessed by an I2 test.
Results: We obtained data from 8 studies that included 68,805 TAVR patients, of whom 1,256 (1.83%) were diagnosed with PVE after TAVR. 280 patients died within the 30-days of PVE diagnosis and the pooled in-hospital mortality was 22.3%. The summary estimates indicated an increased risk of PVE after TAVR for males (RR 1.53, P = .0001); for patients with orotracheal intubation (RR 1.65, P = .01), new pacemaker implantation (RR 1.46, P = .003), and residual aortic regurgitation (≥2 grade) (RR 1.62, P = .05); while older age (RR 0.97, P = .0007) and implantation of a self-expandable valve (RR 0.74, P = .02) were associated with a lower risk of PVE after TAVR.
Conclusion: Clinical characteristics and peri-
procedure factors including age, male sex, valve type, orotracheal intubation, pacemaker implantation, and residual regurgitation were proven to be associated with the occurrence of PVE-TAVR. Clinicians should pay particular attention to PVE when treating TAVR patients with these predictors.
References
Abdel-Wahab M, Neumann FJ, Mehilli J, et al. 2015. 1-year outcomes after transcatheter aortic valve replacement with balloon-expandable versus self-expandable valves: Results from the choice randomized clinical trial. J Am Coll Cardiol 66:791-800.
Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, et al. 2015. Infective endocarditis after transcatheter aortic valve implantation: Results from a large multicenter registry. Circulation 131:1566-74.
Anantha-Narayanan M, Reddy YNV, Sundaram V, et al. 2020. Endocarditis risk with bioprosthetic and mechanical valves: Systematic review and meta-analysis. Heart 106:1413-19.
Athappan G, Patvardhan E, Tuzcu EM, et al. 2013. Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: Meta-analysis and systematic review of literature. J Am Coll Cardiol 61:1585-95.
Bax JJ, Delgado V. 2019. Prosthetic valve endocarditis after surgical and transcatheter aortic valve replacement: Infrequent, but poor outcome. Euro Intervention 15:e484-5.
Ben-Shoshan J, Amit S, Finkelstein A. 2016. Transcatheter aortic valve implantation infective endocarditis: Current data and implications on prophylaxis and management. Curr Pharm Des 22:1959-64.
Bjursten H, Rasmussen M, Nozohoor S, et al. 2019. Infective endocarditis after transcatheter aortic valve implantation: A nationwide study. Eur Heart J 40:3263-9.
Braghiroli J, Kapoor K, Thielhelm TP, Ferreira T, Cohen MG. 2020. Transcatheter aortic valve replacement in low risk patients: A review of partner 3 and EVOLUT low risk trials. Cardiovasc Diagn Ther 10:59-71.
Butt JH, Ihlemann N, De Backer O, et al. 2019. Long-term risk of infective endocarditis after transcatheter aortic valve replacement. J Am Coll Cardiol 73:1646-55.
Fauchier L, Bisson A, Herbert J, et al. 2020. Incidence and outcomes of infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement. Clin Microbiol Infect 26:1368-74.
Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. 2017. Prosthetic valve endocarditis after surgical aortic valve replacement. Circulation 136:329-31.
Higgins JP, Thompson SG. 2002. Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-58.
Kolte D, Goldsweig A, Kennedy KF, et al. 2018. Comparison of incidence, predictors, and outcomes of early infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement in the united states. Am J Cardiol 122:2112-9.
Kuttamperoor F, Yandrapalli S, Siddhamsetti S, Frishman WH, Tang GHL. 2019. Infectious endocarditis after transcatheter aortic valve replacement: Epidemiology and outcomes. Cardiol Rev 27:236-41.
Liberati A, Altman DG, Tetzlaff J, et al. 2009. The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 339:b2700.
Mack MJ, Leon MB, Thourani VH, et al. 2019. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380:1695-705.
Manne MB, Shrestha NK, Lytle BW, et al. 2012. Outcomes after surgical treatment of native and prosthetic valve infective endocarditis. Ann Thorac Surg 93:489-93.
Misawa Y. 2015. Valve-related complications after mechanical heart valve implantation. Surg Today 45:1205-9.
Olsen NT, De Backer O, Thyregod HG, et al. 2015. Prosthetic valve endocarditis after transcatheter aortic valve implantation. Circ Cardiovasc Interv 8:e001939.
Popma JJ, Deeb GM, Yakubov SJ, et al. 2019. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380:1706-15.
Regev E, Finkelstein A, Assali A, et al. 2017. Comparison of outcome of transcatheter aortic valve implantation for severe aortic stenosis in 3 age groups (=70; 71 to 80, and >/=81 years). Am J Cardiol 120:1607-11.
Regueiro A, Linke A, Latib A, et al. 2016. Association between transcatheter aortic valve replacement and subsequent infective endocarditis and in-hospital death. JAMA 316:1083-92.
Regueiro A, Linke A, Latib A, et al. 2019. Infective endocarditis following transcatheter aortic valve replacement: Comparison of balloon- versus self-expandable valves. Circ Cardiovasc Interv 12:e007938.
Tabata N, Al-Kassou B, Sugiura A, et al. 2020. Predictive factors and long-term prognosis of transcatheter aortic valve implantation-associated endocarditis. Clin Res Cardiol 109:1165-76.
Tan HL, Chai LY, Yeo TC, Chia BL, Tambyah PA, Poh KK. 2015. Predictors of in-hospital adverse events in patients with prosthetic valve infective endocarditis. Heart Lung Circ 24:705-9.
Thyregod HG, Steinbruchel DA, Ihlemann N, et al. 2015. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers notion randomized clinical trial. J Am Coll Cardiol 65:2184-94.
Waksman R, Rogers T, Torguson R, et al. 2018. Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis. J Am Coll Cardiol 72:2095-105.
Young Lee M, Chilakamarri Yeshwant S, Chava S, Lustgarten LD. 2015. Mechanisms of heart block after transcatheter aortic valve replacement - cardiac anatomy, clinical predictors and mechanical factors that contribute to permanent pacemaker implantation. Arrhythm Electrophysiol Rev 4:81-5.
